Sex differences in drug metabolism: Cytochrome P-450 and uridine diphosphate glucuronosyltransferase

Journal of Gender-Specific Medicine

Volumn 5, Issue 1, 2002, Pages 25-33

  Anderson, Gail D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ALPRAZOLAM; AMIODARONE; CYCLOSPORIN; CYTOCHROME P450; DAPSONE; DIAZEPAM; DICLOFENAC; DILTIAZEM; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; GLUCURONOSYLTRANSFERASE; IBUPROFEN; KETOPROFEN; METHADONE; METHYLPREDNISOLONE; MIDAZOLAM; MODAFINIL; NEFAZODONE; NEVIRAPINE; NIFEDIPINE; PHENYTOIN; PIROXICAM; PREDNISOLONE; PROPRANOLOL; TIRILAZAD; TOLBUTAMIDE; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ETHNOLOGY; FEMALE; GENETICS; HUMAN; INCIDENCE; MALE; PHYSIOLOGY; REVIEW; SEX DIFFERENCE; X CHROMOSOME LINKAGE;

AGE FACTORS; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CONTINENTAL POPULATION GROUPS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; PHARMACEUTICAL PREPARATIONS; SEX FACTORS; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0036254424     PISSN: 15237036     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. The human hepatic cytochrome P450 involved in drug metabolism
2. Geographical/interracial differences in polymorphic drug oxidation: Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19
3. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases
4. Noninvasive tests of CYP3A enzymes
5. Interindividual variation in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: Studies with the microsomes of 30 Japanese and 30 Caucasians
6. Effect of age and gender on the activity of human hepatic CYP3A
7. Intersubject and dose-related variability after intravenous administration of erythromycin
8. Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity
9. Gender-based effects of methylprednisolone pharmacokinetics and pharmacodynamics
10. Alterations in prednisolone disposition as a result of time of administration, gender and dose
11. Effect of age and gender on tirilazad pharmacokinetics in humans
12. Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts
13. Open-label, single-dose pharmacokinetic study of modafinil tablets: Influence of age and gender in normal subjects
14. Gender related pharmacokinetics of diltiazem in healthy subjects
15. Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay
16. Age-dependent cyclosporine: Pharmacokinetics in marrow transplant recipients
17. Aging and alfentanil disposition in healthy volunteers and surgical patients
18. Influence of age on the pharmacokinetics of alfentanil: Gender dependence
19. Effect of age, gender, and obesity on midazolam kinetics
20. Effects of age, gender and oral contraceptives on intramuscular midazolam pharmacokinetics
21. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam
22. Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans
23. Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics
24. The effects of age and gender on the stereoselective pharmacokinetics of verapamil
25. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population
26. Influence of menstrual cycle and gender on alprazolam pharmacokinetics
27. Population pharmacokinetics of intravenous amiodarone in patients with refractory ventricular tachycardia/fibrillation
28. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses
29. Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment
30. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients
31. Differences in the urinary excretion of 6-beta-hydroxycortisol/cortisol between Asian and Caucasian women
32. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism
33. Population pharmacokinetics of racemic warfarin in adult patients
34. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy
35. Tolbutamide hydroxylation in humans: Lack of bimodality in 106 healthy subjects
36. Piroxicam and naproxen plasma concentrations in patients with osteoarthritis: Relation to age, sex, efficacy and adverse events
37. Effects of age and sex on piroxicam disposition
38. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes
39. Lack of effect of gender and oral contraceptive steroids on the pharmacokinetics of (R)-ibuprofen in humans
40. Stereoselective pharmacokinetics and inversion of (R)-ketoprofen in healthy volunteers
41. Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients
42. Phenytoin dosage requirements and pharmacokinetic variables
43. Population pharmacokinetics of phenytoin in Singapore Chinese
44. Factors influencing the population pharmacokinetic parameters of phenytoin in adult epileptic patients in South Africa
45. Phenytoin hydroxylation in healthy Caucasian population: Bimodal distribution of hydroxyphenytoin urinary excretion
46. Plasma diphenylhydantoin levels in Australian adults
47. The effects of dose, age, and sex on the serum levels of phenobarbital and diphenylhydantoin in epileptic patients
48. Effect of age, height, weight and sex on serum phenytoin concentrations in epileptic patients
49. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world
50. Genetic analysis of S-mephenytoin polymorphism in a Chinese population
51. Evidence for the effect of gender on activity of (S)-mephenytoin 4′-hydroxylase (CYP2C19) in a Chinese population
52. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: Indications for oral contraceptive-related gender differences
53. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G->A- splice site mutation
54. Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man
55. The mephenytoin (cytochrome P450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos
56. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population
57. Genetic polymorphism of S-mephenytoin 4′-hydroxylation in African-Americans
58. Diazepam kinetics in relation to age and sex
59. Diazepam disposition determinants
60. Age- and gender-related differences in diazepam pharmacokinetics
61. Pathway selective sex differences in the metabolic clearance of propranolol in human subjects
62. Preliminary study of the pharmacokinetics of desmethyldiazepam as drops or tablets
63. The influence of age and gender on the stereoselective metabolism and pharmacokinetics of mephobarbital in humans
64. A preliminary note on the transient polymorphic oxidation of sparteine in the Ngawbe Guaymi Amerindians: A case of genetic divergence with tentative phylogenetic time frame for the pathway
65. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in a Chinese population
66. Evidence for the polymorphic oxidation of debrisoquine in the Thai population
67. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology
68. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping
69. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations
70. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
71. Gender differences in hepatic induction and inhibition of theophylline pharmacokinetics and metabolism
72. Racial and gender differences in N- acetyltransferase, xanthine oxidase, and CYP1A2 activities
73. Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population
74. The influence of ethnic factors and gender on CYP1A2 -mediated drug disposition: A comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate
75. Effects of gender and age on plasma levels of clozapine and its metabolites: Analyzed by critical statistics
76. Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: Formulation and gender differences
77. Sex-related differences in theophylline pharmacokinetics
78. Application of population pharmacokinetics to the optimization of theophylline therapy
79. Clinical importance of hepatic cytochrome P450 in drug metabolism
80. Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects
81. In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians
82. The uridine diphosphate glucuronosyltransferase multigene family; Function and regulation
83. The UDP glucuronosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence
84. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation
85. Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam
86. Effect of age and gender on disposition of temazepam
87. Oxazepam kinetics: Effect of age and sex
88. Influence of sex and oral contraceptive steroids on paracetamol metabolism
89. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes
90. Gender and oral contraceptive steroids as determinants of drug glucuronidation: Effects on clofibric acid elimination
91. Sex-difference and the effects of smoking and oral contraceptive steroids on the kinetics of diflunisal
92. Urinary glucuronide excretion of fenofibric and clofibric acid glucuronides in man: Is it polymorphic?
93. Ethnic differences in N-glucuronidation of nicotine and cotinine